Genetically validated targets are 2.6 times more likely to win approval
Start here
A Regeneron geneticist lays out the case for using human genetics to guide drug discovery, arguing that natural mutations act as ready-made clinical trials. The core statistic: drug targets with human genetic support are roughly 2.6 times more likely to reach approval than targets without it. Examples cited range from CCR5 to HAO1 knockouts, illustrating how loss-of-function and other variants found in human populations can reveal which targets are worth pursuing before a molecule enters the clinic. The discussion, hosted on Reddit, is a community exchange rather than a peer-reviewed publication, and the broader question of how widely genetic validation can be applied across therapeutic areas remains open.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 20 21:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.